Chemical Tags on Blood Proteins Reveal a New Window Into Alzheimer’s Disease

Alzheimer’s disease has long been diagnosed by its consequences rather than its chemistry. Memory tests, brain scans and, more recently, fluid biomarkers all track the damage wrought by misfolded amyloid and tau proteins, yet the molecular events unfolding in the bloodstream of a living patient remain far less charted territory. A new study from researchers at the University of Tokyo, published in the journal Clinical Proteomics, argues that a crucial layer of that chemistry has been almost entirely overlooked: the small chemical tags that decorate blood proteins after they are made. By systematically mapping one of the most influential of these modifications, lysine acetylation, across the plasma of Alzheimer’s patients and healthy controls, the team has produced the first acetylation-directed proteomic landscape of the disease in human blood.

The modification at the heart of the study is deceptively simple. Lysine is one of the twenty amino acids that make up proteins, and when a small acetyl group is attached to its side chain, the physics of the protein changes. Acetylation can neutralize a positive charge, alter how the protein folds, reshape the surfaces it uses to bind partners, change how long it survives in circulation, and modulate its enzymatic activity. Because a single protein can carry acetyl groups at many different lysine positions, each with potentially distinct consequences, the modification multiplies the functional diversity of the proteome many times over. In cells and tissues, lysine acetylation is famous as a regulator of gene expression and metabolism; in blood plasma, the protein-rich, cell-free fraction of blood, it has been far less systematically explored, particularly in the context of neurodegenerative disease.

To capture this hidden layer, the researchers turned to mass spectrometry, the workhorse technology of modern proteomics. In this approach, proteins extracted from plasma are broken into short peptide fragments, which are then separated by liquid chromatography and fired into a mass spectrometer. The instrument fragments each peptide further and records the resulting spectra, from which the identity of the parent protein and the exact position of any chemical modification can be inferred. Crucially, the team enriched specifically for acetylated peptides before analysis, a step that is essential because acetylated peptides are typically rare amid the overwhelming abundance of unmodified material in plasma. Without such enrichment, the signal from these modified peptides would drown in noise.

The scale of the resulting dataset is what sets the study apart. From plasma samples obtained from twenty Alzheimer’s disease patients and twenty age-matched controls, the researchers acquired more than 7,600 independent tandem mass spectrometry spectral measurements corresponding to 350 unique lysine acetylation sites. Each of those sites represents a specific lysine residue on a specific plasma protein where an acetyl group was detected and localized. This is not merely a catalog of proteins present in blood, which earlier plasma proteomics efforts have assembled in depth, but a map of where on each protein the chemical decoration occurs, in a clinical context where such information did not previously exist.

The study is, according to its authors, the first lysine acetylation-directed proteomic landscape of Alzheimer’s-related human plasma samples. That first matters because plasma is where blood-based diagnostics for Alzheimer’s are increasingly being developed. Current leading biomarkers, such as measures of phosphorylated tau in plasma, focus on a different post-translational modification, phosphorylation, and on proteins that originate in the brain. Acetylation offers a complementary view: it reports on the state of the abundant plasma proteome itself, including lipoproteins, complement factors, coagulation proteins and carriers that mediate inflammation, lipid transport and immune signaling, all of which are increasingly implicated in Alzheimer’s pathogenesis through large-scale genetic and epidemiological studies.

Among the proteins carrying acetylation marks, apolipoproteins stand out as a biologically plausible focus. These lipid-binding proteins shuttle cholesterol and other fats through the bloodstream, and the strongest genetic risk factor for late-onset Alzheimer’s disease, the APOE gene, encodes an apolipoprotein. The study’s abbreviation list also flags low-density lipoprotein, the cholesterol-carrying particles whose biology intersects with both cardiovascular and neurodegenerative disease, suggesting that acetylation states on lipid transport machinery were among the features captured in the dataset. How acetylation alters the function of these carriers, and whether specific acetylation patterns track with disease status, are questions the dataset now makes answerable.

Perhaps the most unexpected dimension of the work lies beyond canonical proteins altogether. The mass spectrometry measurements detected acetylated peptide sequences that do not map to the standard catalog of human proteins. Instead, they correspond to short open reading frames, stretches of the genome that ribosome profiling technologies have shown are actively translated into tiny peptides even though they were long dismissed as non-coding. The idea that such non-canonical peptides circulate in plasma, and that they carry lysine acetylation marks detectable by mass spectrometry, expands the searchable space of blood-borne molecules. It hints that the plasma proteome is even less fully inventoried than assumed, and that some disease-relevant signals may reside in proteins that standard annotation pipelines ignore.

Methodologically, the study reflects the demanding craft of plasma proteomics. The authors employed filter-aided sample preparation, a technique that uses molecular-weight filters to clean and digest protein samples, and combined complementary fragmentation methods, collision-induced dissociation and higher-energy collisional dissociation, to maximize the information extracted from each peptide. Quantification was performed label-free, comparing spectral intensities across samples rather than relying on chemical tags introduced beforehand. The abbreviation NSRP1, for nuclear speckle splicing regulatory protein 1, appears in the study’s key terms, indicating that even proteins not normally thought of as plasma residents contributed identifiable acetylated peptides to the landscape.

The study design itself was deliberately controlled. Twenty patients with Alzheimer’s disease and twenty age-matched controls provide a matched comparison in which age, the strongest demographic risk factor, is held constant. The plasma samples were obtained from a commercial vendor operating under applicable regulations for the collection and handling of biological specimens, which the authors note meant separate ethics approval was not required. The work was funded by a Grant-in-Aid for Transformative Research Areas from Japan’s Ministry of Education, Culture, Sports, Science and Technology, with additional research funding from Abbott Laboratories, and one co-author is an employee of Abbott Japan, a disclosure the authors make explicitly in the paper.

What the study does not yet claim is a diagnostic test. A landscape of 350 acetylation sites across forty individuals is a foundation, not a finished clinical instrument. Validating any individual acetylation site as a biomarker will require larger and more diverse cohorts, longitudinal sampling, and confirmation that the modification patterns are reproducible across laboratories and platforms. The authors frame their contribution accordingly: as a resource that may contribute to a more extensive understanding of the biochemical properties of human plasma protein components in relation to Alzheimer’s disease pathogenesis. In a field racing toward blood-based early detection, the message of the study is that the blood itself still holds layers of information, written in chemical tags, that science is only now learning to read.

Subject of Research: Lysine acetylation profiling of plasma proteins in Alzheimer's disease using mass spectrometry

Article Title: Lysine acetylation-directed high-resolution plasma proteomic landscape of Alzheimer’s disease

Article References: Kozuka-Hata, H., Kitamura, A., Hiroki, T., Miyamura, N., Yoshimura, T., Tsumoto, K., & Oyama, M. (2026). Lysine acetylation-directed high-resolution plasma proteomic landscape of Alzheimer’s disease. Clinical Proteomics. https://doi.org/10.1186/s12014-026-09635-y

Image Credits: AI Generated

DOI: 10.1186/s12014-026-09635-y

Keywords: Alzheimer's disease, plasma proteomics, lysine acetylation, mass spectrometry, post-translational modification, apolipoprotein, short open reading frame, biomarkers, Clinical Proteomics, blood-based diagnostics, Lysine, acetylation-directed